Abdulrahman Alissa
Overview
Explore the profile of Abdulrahman Alissa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alissa A, Korayem G, Aljuhani O, AlFaifi M, Alnajjar L, Souaan N, et al.
Ther Clin Risk Manag
. 2025 Feb;
21:177-189.
PMID: 40008079
Background: Limited evidence is available regarding the safety and effectiveness of early high protein intake in critically ill patients with COVID-19. Therefore, this study aims to assess the safety of...
2.
Basilim A, Eljaaly K, Aljuhani O, Korayem G, Altebainawi A, Aldhmadi W, et al.
J Intensive Care Med
. 2024 Nov;
40(1):74-84.
PMID: 39552466
Dexmedetomidine (DEX) is a highly favored sedative agent in critically ill patients owing to its anxiolytic and analgesic properties, lower risk of delirium, and minimal respiratory depression. Additionally, DEX exhibits...
3.
Alissa A, Alrashed M, Alshaya A, Al Sulaiman K, Alharbi S
Front Med (Lausanne)
. 2024 Nov;
11:1476242.
PMID: 39540046
Vitamin C (Ascorbic acid) has evolved as an emergent co-intervention for sepsis and septic shock patients. Multiple studies discussed the pathophysiological value of vitamin C to reserve endothelial functionality and...
4.
Al Sulaiman K, Korayem G, Aljuhani O, Altebainawi A, Shawaqfeh M, Alarfaj S, et al.
Front Med (Lausanne)
. 2023 Sep;
10:1237903.
PMID: 37692775
Background: Despite insufficient evidence, vitamin D has been used as adjunctive therapy in critically ill patients with COVID-19. This study evaluates the effectiveness and safety of vitamin D as an...
5.
Al Sulaiman K, Aljuhani O, Korayem G, Alnajjar L, Altebainawi A, AlFaifi M, et al.
Clin Appl Thromb Hemost
. 2023 Jun;
29:10760296231177017.
PMID: 37322869
Doxycycline has revealed potential effects in animal studies to prevent thrombosis and reduce mortality. However, less is known about its antithrombotic role in patients with COVID-19. Our study aimed to...
6.
Aljuhani O, Korayem G, Altebainawi A, Al Harthi A, Badreldin H, Alsalloum M, et al.
J Intensive Care Med
. 2023 Jan;
38(6):534-543.
PMID: 36683420
Tocilizumab (TCZ) has been proposed as potential rescue therapy for severe COVID-19. No previous study has primarily assessed the role of TCZ in preventing severe COVID-19-related multiorgan dysfunction. Hence, this...
7.
Al Sulaiman K, Aljuhani O, Korayem G, Hafiz A, Alalawi M, Badreldin H, et al.
Thromb J
. 2022 Dec;
20(1):74.
PMID: 36482388
Background: Thrombotic events are common in critically ill patients with COVID-19 and have been linked with COVID-19- induced hyperinflammatory state. In addition to anticoagulant effects, heparin and its derivatives have...
8.
Al Sulaiman K, Korayem G, Altebainawi A, Al Harbi S, Alissa A, Alharthi A, et al.
Crit Care
. 2022 Oct;
26(1):304.
PMID: 36192801
Background: Inhaled nitric oxide (iNO) is used as rescue therapy in patients with refractory hypoxemia due to severe COVID-19 acute respiratory distress syndrome (ARDS) despite the recommendation against the use...
9.
Al Sulaiman K, Korayem G, Eljaaly K, Altebainawi A, Al Harbi O, Badreldin H, et al.
Sci Rep
. 2022 Jun;
12(1):9766.
PMID: 35697822
Dexamethasone showed mortality benefits in patients with COVID-19. However, the optimal timing for dexamethasone initiation to prevent COVID-19 consequences such as respiratory failure requiring mechanical ventilation (MV) is debatable. As...
10.
Al Harbi S, Kensara R, Aljuhani O, Korayem G, Altebainawi A, Al Harthi A, et al.
Clin Appl Thromb Hemost
. 2022 Jun;
28:10760296221103864.
PMID: 35658686
Purpose: Coagulation abnormalities are one of the most important complications of severe COVID-19, which might lead to venous thromboembolism (VTE). Hypercoagulability with hyperfibrinogenemia causes large vessel thrombosis and major thromboembolic...